Document is current
Any future updates will be listed below
-
Authors
Hurlburt, Nicholas K. https://orcid.org/0000-0001-9891-916X
Homad, Leah J. https://orcid.org/0000-0001-8421-6519
Sinha, Irika https://orcid.org/0000-0001-6440-7019
Jennewein, Madeleine F.
MacCamy, Anna J.
Wan, Yu-Hsin
Boonyaratanakornkit, Jim https://orcid.org/0000-0001-5858-2662
Sholukh, Anton M. https://orcid.org/0000-0003-0498-9162
Jackson, Abigail M. https://orcid.org/0000-0001-9749-9431
Zhou, Panpan https://orcid.org/0000-0001-5740-4303
Burton, Dennis R. https://orcid.org/0000-0001-6711-9864
Andrabi, Raiees https://orcid.org/0000-0001-8837-7520
Ozorowski, Gabriel https://orcid.org/0000-0002-9695-8138
Ward, Andrew B. https://orcid.org/0000-0001-7153-3769
Stamatatos, Leonidas https://orcid.org/0000-0002-1106-7097
Pancera, Marie https://orcid.org/0000-0001-9217-6270
McGuire, Andrew T. https://orcid.org/0000-0003-1841-6859
-
Funding
Funding for this research was provided by:
Fast Grants
Fred Hutch COVID-19 Research Fund
M.J. Murdock Charitable Trust
- License Information
-
More Information
Article History
Received: 10 January 2022
Accepted: 11 March 2022
First Online: 11 April 2022
Competing interests
: L.S., M.P., and A.T.M. are inventors on a provisional patent application No. 63/131599 filed by the Fred Hutchinson Cancer Research Center on the CV3-25 monoclonal antibody. A.T.M. is an inventor on a provisional patent application No. 63/108,554 filed by the University of Washington on the B6 monoclonal antibody. All other authors declare no competing interests.
